Author

Susanne Schmitt

Observed names: S Schmitt, Schmitt, S.

ORCID: 0009-0006-6713-614X

Observed ORCID: 0009-0006-6713-614X

OpenAlex ID: A5113166837

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 337

PDF

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2021 · Gregory G. Schwartz, Michael Szarek, et al. · Journal of the American College of Cardiology · 161

PDF

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 123

PDF

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

2018 · Stanley B. Cohen, Rieke Alten, et al. · Arthritis Research & Therapy · 65

PDF

Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial

2022 · Axel Bauer, Nikolay Sappler, et al. · The Lancet Digital Health · 40

PDF

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40

PDF

Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES

2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 31

PDF

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 28

PDF

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease

2017 · Matthew R. Weir, Pablo E. Pergola, et al. · American Journal of Nephrology · 12

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients

2017 · Nicole Casadevall, Vladimir Dobronravov, et al. · Clinical Nephrology · 10

PDF

Implementation of the Anchor-Based Indirect Comparison Method for Equivalence Margin Derivation in Biosimilar Development

2025 · Claudia Hemmelmann, Rachid El Galta, et al. · Pharmaceuticals · 3

PDF

P554 Incidence and impact of immunogenicity in a randomised, double-blind phase III study comparing a proposed infliximab biosimilar (PF-06438179/GP1111) with reference infliximab

2018 · R Palaparthy, S Schmitt, et al. · Journal of Crohn s and Colitis · 1

Trial Probability of Success for Testing 3‐Way PK/PD Similarity With Multiple Endpoints

2025 · Rachid el Galta, Susanne Schmitt, et al. · Pharmaceutical Statistics

Statistical principles in biosimilar development

2019 · Alison Balfour, Susanne Schmitt · Medical Writing

Supplementary Material for: A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease

2017 · Weir, M.R., Pergola, P.E., et al. · Figshare

Sp312evaluation of the Safety and Immunogenicity of Subcutaneous (sc) Hx575 Epoetin Alfa in the Treatment of Anaemia Associated With Ckd

2016 · Nicole Casadevall, Vladimir Dobronravov, et al. · Nephrology Dialysis Transplantation

Works count: 16

Citation count: 851

H-index: 10

I10-index: 10